WFRF:(Linseman J.)
Sökning: WFRF:(Linseman J.) > Effects of low-dose...
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04306naa a2200481 4500 | |
| 001 | oai:gup.ub.gu.se/107507 | |
| 003 | SwePub | |
| 008 | 240910s2009 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://gup.ub.gu.se/publication/1075072 URI |
| 040 | a (SwePub)gu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Metra, M.4 aut |
| 245 | 1 0 | a Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials |
| 264 | 1 | c 2009 |
| 520 | a AIMS: Use of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase benefit-risk ratio. We investigated the effects of low doses of the positive inotrope enoximone on symptoms, exercise capacity, and major clinical outcomes in patients with advanced HF who were also treated with beta-blockers and other guideline-recommended background therapy. METHODS AND RESULTS: The Studies of Oral Enoximone Therapy in Advanced HF (ESSENTIAL) programme consisted of two identical, randomized, double-blind, placebo-controlled trials that differed only by geographic location (North and South America: ESSENTIAL-I; Europe: ESSENTIAL-II). Patients with New York Heart Association class III-IV HF symptoms, left ventricular ejection fraction < or = 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous year were eligible for participation in the trials. The trials had three co-primary endpoints: (i) the composite of time to all-cause mortality or cardiovascular hospitalization, analysed in the two ESSENTIAL trials combined; (ii) the 6 month change from baseline in the 6 min walk test distance (6MWTD); and (iii) the Patient Global Assessment (PGA) at 6 months, both analysed in each trial separately. ESSENTIAL-I and -II randomized 1854 subjects at 211 sites in 16 countries. In the combined trials, all-cause mortality and the composite, first co-primary endpoint did not differ between the two treatment groups [hazard ratio (HR) 0.97; 95% confidence interval (CI) 0.80-1.17; and HR 0.98; 95% CI 0.86-1.12, respectively, for enoximone vs. placebo]. The two other co-primary endpoints were analysed separately in the two ESSENTIAL trials, as prospectively designed in the protocol. The 6MWTD increased with enoximone, compared with placebo, in ESSENTIAL-I (P = 0.025, not reaching, however, the pre-specified criterion for statistical significance of P < 0.020), but not in ESSENTIAL-II. No difference in PGA was observed in either trial. CONCLUSION: Although low-dose enoximone appears to be safe in patients with advanced HF, major clinical outcomes are not improved. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
| 700 | 1 | a Eichhorn, E.4 aut |
| 700 | 1 | a Abraham, W. T.4 aut |
| 700 | 1 | a Linseman, J.4 aut |
| 700 | 1 | a Bohm, M.4 aut |
| 700 | 1 | a Corbalan, R.4 aut |
| 700 | 1 | a Demets, D.4 aut |
| 700 | 1 | a De Marco, T.4 aut |
| 700 | 1 | a Elkayam, U.4 aut |
| 700 | 1 | a Gerber, M.4 aut |
| 700 | 1 | a Komajda, M.4 aut |
| 700 | 1 | a Liu, P.4 aut |
| 700 | 1 | a Mareev, V.4 aut |
| 700 | 1 | a Perrone, S. V.4 aut |
| 700 | 1 | a Poole-Wilson, P.4 aut |
| 700 | 1 | a Roecker, E.4 aut |
| 700 | 1 | a Stewart, J.4 aut |
| 700 | 1 | a Swedberg, Karl,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xsweka |
| 700 | 1 | a Tendera, M.4 aut |
| 700 | 1 | a Wiens, B.4 aut |
| 700 | 1 | a Bristow, M. R.4 aut |
| 710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin4 org |
| 773 | 0 | t European Journal of Heart Failureg 30:24, s. 3015-26q 30:24<3015-26x 1522-9645 |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/107507 |
Hitta via bibliotek
- European Journal of Heart Failure (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 1 av 1
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Metra, M.
- Eichhorn, E.
- Abraham, W. T.
- Linseman, J.
- Bohm, M.
- Corbalan, R.
- visa fler...
- Demets, D.
- De Marco, T.
- Elkayam, U.
- Gerber, M.
- Komajda, M.
- Liu, P.
- Mareev, V.
- Perrone, S. V.
- Poole-Wilson, P.
- Roecker, E.
- Stewart, J.
- Swedberg, Karl, ...
- Tendera, M.
- Wiens, B.
- Bristow, M. R.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- European Journal ...
- Av lärosätet
- Göteborgs universitet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
